Back to News
Mergers & Acquisitions

IFF Backs Into DuPont Nutrition & Science

By Paul Whitfield
|
Published: June 22nd, 2020
The reverse takeover values the DuPont unit at $26.2 billion.

DuPont Inc. (DD) shareholders will receive a majority stake in a new $45.4 billion food ingredients business after International Flavors & Fragrance Inc. (IFF) agreed to a reverse takeover of DuPont Nutrition & Biosciences.

Under the terms of the deal, announced on Sunday, Dec. 15, IFF will swap stock for DuPont shares, leaving the latter’s shareholders with 55.4% of the combined business. DuPont will also receive a one-time $7.3 billion cash payment once the deal closes, boosting the enterprise value of DuPoint N&B in the deal to $26.2 billion.

IFF said the deal will be structured as a Reverse Morris Trust, a structure that will combine a spin-off of the DuPont unit with its acquisition, enabling DuPont to secure the deal on a tax-free basis.

The resulting company, which will trade as IFF, will have pro-forma revenues of $11 billion and Ebitda of $2.6 billion, including expected cost savings and other synergies, making it one of the biggest providers of ingredients to the food and beverage sector as well as a major player in the home, personal care, health and wellbeing sectors.

Editor’s note: The original version of this article, including advisers and other details, was published earlier on The Deal’s premium subscription website. For access, log in to TheDeal.com or use the form below to request a free trial.

This Content is Only for The Deal Subscribers

The Deal provides actionable, intraday coverage of mergers, acquisitions and all other changes in corporate control to institutional investors, private equity, hedge funds and the firms that serve them.

If you’re already a subscriber, log in to view this article here.

More From Mergers & Acquisitions

Mergers & Acquisitions

Drinks With The Deal Podcast: Paul Hastings' Steve Camahort

By David Marcus
|
Published: June 16th, 2022
On this week's Drinks With The Deal podcast, Steve Camahort, the chair of global M&A at Paul Hastings, discusses Elon Musk's bid for Twitter as well as the evolution of tech PE and the Bay Area legal market.